Brilinta

Brilinta is a brand name of ticagrelor, approved by the FDA in the following formulation(s):

BRILINTA (ticagrelor - tablet; oral)

• 
  Manufacturer: ASTRAZENECA LP
  
  Approval date: July 20, 2011
  
  Strength(s): 90MG ^[RLD]

Has a generic version of Brilinta been approved?

No. There is currently no therapeutically equivalent version of Brilinta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Brilinta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
  Patent 6,251,910
  Issued: June 26, 2001
  Inventor(s): Guile; Simon & Ingall; Anthony & Springthorpe; Brian & Willis; Paul
  Assignee(s): AstraZeneca UK Limited
  Compounds of formula having the following stereochemistry ##STR1## wherein R, R.sup.1, R.sub.2, R.sup.3 and R.sup.4 are as defined in the specification. The compounds are useful as P.sub.2T receptor antagonists.
  
  Patent expiration dates:
  
  
  • July 15, 2018
    
    ✓ 
    Drug substance
  
  



• 
  Triazolo(4,5-d)pyrimidine compounds
  Patent 6,525,060
  Issued: February 25, 2003
  Inventor(s): David; Hardern & Anthony; Ingall & Brian; Springthorpe & Paul; Willis & Simon; Guile
  Assignee(s): Astrazeneca UK Limited
  Triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. The compounds of the invention have the formula (I) as follows: wherein R, X and R1 through R3 are as defined in the specification.
  
  Patent expiration dates:
  
  
  • December 2, 2019
    
    ✓ 
    Patent use: REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
  Patent 7,250,419
  Issued: July 31, 2007
  Inventor(s): Hardern; David & Ingall; Anthony & Springthorpe; Brian & Willis; Paul & Guile; Simon
  Assignee(s): AstraZeneca AB
  The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
  
  Patent expiration dates:
  
  
  • December 2, 2019
    
    ✓ 
    Patent use: REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
  Patent 7,265,124
  Issued: September 4, 2007
  Inventor(s): Bohlin; Martin & Cosgrove; Steve & Lassen; Bo
  Assignee(s): AstraZeneca AB
  The invention provides new forms of a chemical compound of formula (I). The invention relates to forms of a chemical compound (I), in particular to crystalline and amorphous forms, more particularly four crystalline forms and an amorphous form. The invention further relates to processes for the preparation of such forms, to pharmaceutical compositions comprising the compound in crystalline and/or amorphous form and to therapeutic use of such forms.
  
  Patent expiration dates:
  
  
  • July 9, 2021
    
    ✓ 
    Patent use: REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 20, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Brilinta Consumer Information (Drugs.com)
• Brilinta Consumer Information (Wolters Kluwer)
• Brilinta Consumer Information (Cerner Multum)
• Ticagrelor Consumer Information (Wolters Kluwer)
• Ticagrelor Consumer Information (Cerner Multum)